RhumbLine Advisers’s Arcturus Therapeutics ARCT Stock Holding History
Bought
Maintained
Sold
Other funds holding ARCT
RhumbLine Advisers's ARCT Position: Q3 2026 in Review
RhumbLine Advisers increased its Arcturus Therapeutics (ARCT) stake by 3.9% in Q3 2026, buying an estimated $12.9K and bringing the position to 33,119 shares worth $453K. The position accounts for ﹤0.01% of the portfolio, ranked #2793.
RhumbLine Advisers first reported a position in ARCT in Q2 2020 and has held it in 26 quarters since. The position peaked at $1.42M in Q3 2021. 155 funds tracked by Wall St. Rank hold ARCT as of Q3 2026.
- RhumbLine Advisers held 33,119 shares of Arcturus Therapeutics worth $453K as of Q3 2026.
- RhumbLine Advisers bought 1,232 Arcturus Therapeutics shares in Q3 2026, an estimated $12.9K.
- Arcturus Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q3 2026, its #2793 holding.
- RhumbLine Advisers first reported a position in Arcturus Therapeutics in Q2 2020 and has held it in 26 quarters since.
- RhumbLine Advisers's Arcturus Therapeutics position peaked at $1.42M in Q3 2021.
- 155 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2026.
Based on RhumbLine Advisers's 13F filing for Q3 2026, filed 10 Nov 2026.